

12 August 2024

**Graft Polymer (UK) Plc**  
**("Graft Polymer" or the "Company")**

**Director resignation**

Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery systems development company, announces the resignation, with immediate effect, of Yifat Steuer from its board of directors and from the role of Chief Financial Officer.

Orana Corporate LLP will continue to provide support in relation to the Company's financial function whilst the Company proceeds to select a new CFO.

**Nicholas Nelson, Chairman, commented:**

*"Yifat departs us with our sincere thanks for all she has done during the transitional period since I became Chairman. She has provided us with invaluable guidance and professionalism.*

*"New board appointments are planned to steer the Company as it pursues its mission to innovate in drug delivery solutions. "*

**Enquiries:**

Graft Polymer (UK) Plc  
Anthony Tennyson, CEO and Executive Director  
Email: [anthonytennyson@graftpolymer.co.uk](mailto:anthonytennyson@graftpolymer.co.uk)

**Allenby Capital (Broker)**

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)  
+44 (0) 20 3328 5656

**About Graft Polymer (UK) Plc**

Graft Polymer plc ("Graft Polymer") (LON: GPL) is an innovative biopolymer drug delivery systems development company dedicated to enabling biopharmaceutical companies to enhance the effectiveness of their therapeutics. Our proprietary platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the pharmacokinetics, bioavailability, and stability of their therapeutics.

For more information, please visit [www.graftpolymer.co.uk](http://www.graftpolymer.co.uk).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAGCGDIGDBGSD